Author Archives: Warren Woessner

Senate Subcommittee on IP Holds Hearings on SWOT of STRONGER Bill

Posted on September 16, 2019 by Warren Woessner

This bill has been introduced into both houses of Congress in a bipartisan effort to curb the reach of inter partes review (IPR) proceedings and the broad four-factor analysis for injunctive relief set forth by the Supreme Court in eBay … Continue reading →

Posted in AIA Patent Reform, Inter Partes Review | Tagged , , | Leave a comment

INO v. Praxair – Method-by-Selection Claims Fail Mayo/Alice Test

Posted on September 3, 2019 by Warren Woessner

In Ino Therapeutics LLC v. Praxair Distrib., Inc., Appeal no.2018-1019 (Fed. Cir., August 27, 2019) a divided Fed. Cir. panel comprising Judges Dyk and Prost, Newman dissenting affirmed a district court decision that a number of INO’s patent claims were … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Nalproprion v. Actavis: WDR met by Substantially Equivalent Claim Elements(?)

Posted on August 27, 2019 by Warren Woessner

In Nalproprion v Actavis, App. No. 2018-1221 (Fed. Cir., August 15, 2019) a divided panel of Judges Prost, Lourie and Wallach – Prost dissenting – affirmed the district court’s ruling that claim 11 of U.S. Pat. No. 8,916,195 met the … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , | Leave a comment

Genotyping Patent Claims Do Not Escape The Reach of s. 101

Posted on August 12, 2019 by Warren Woessner

In Genetic Veterinary Sciences, Inc. v. Laboklin GMBH & Co., the University of Berlin, App. No. 2018-1565 (Fed. Cir., Aug. 9, 2019), a Fed. Cir. panel affirmed the district court’s JMOL ruling that the claims of the University’s U.S. Pat. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment